JP7082130B2 - Tyk2阻害剤およびその使用 - Google Patents

Tyk2阻害剤およびその使用 Download PDF

Info

Publication number
JP7082130B2
JP7082130B2 JP2019541679A JP2019541679A JP7082130B2 JP 7082130 B2 JP7082130 B2 JP 7082130B2 JP 2019541679 A JP2019541679 A JP 2019541679A JP 2019541679 A JP2019541679 A JP 2019541679A JP 7082130 B2 JP7082130 B2 JP 7082130B2
Authority
JP
Japan
Prior art keywords
nitrogen
sulfur
oxygen
disorder
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019541679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535807A5 (cg-RX-API-DMAC7.html
JP2019535807A (ja
Inventor
ジェレミー ロバート グリーンウッド,
ジェラルディン シー. ハリマン,
デ モラディ, シルヴァーナ マルセル リート
クレッグ イー. マッセ,
トーマス エイチ. マックリーン,
サヤン モンデール,
Original Assignee
ニンバス ラクシュミ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニンバス ラクシュミ, インコーポレイテッド filed Critical ニンバス ラクシュミ, インコーポレイテッド
Publication of JP2019535807A publication Critical patent/JP2019535807A/ja
Publication of JP2019535807A5 publication Critical patent/JP2019535807A5/ja
Priority to JP2022000195A priority Critical patent/JP7498200B2/ja
Application granted granted Critical
Publication of JP7082130B2 publication Critical patent/JP7082130B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2019541679A 2016-10-14 2017-10-13 Tyk2阻害剤およびその使用 Active JP7082130B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022000195A JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201662408464P 2016-10-14 2016-10-14
US62/408,464 2016-10-14
US201662410334P 2016-10-19 2016-10-19
US201662410327P 2016-10-19 2016-10-19
US62/410,334 2016-10-19
US62/410,327 2016-10-19
US201662413829P 2016-10-27 2016-10-27
US62/413,829 2016-10-27
US201662415920P 2016-11-01 2016-11-01
US62/415,920 2016-11-01
US201762468807P 2017-03-08 2017-03-08
US201762468767P 2017-03-08 2017-03-08
US201762468749P 2017-03-08 2017-03-08
US62/468,749 2017-03-08
US62/468,807 2017-03-08
US62/468,767 2017-03-08
US201762546278P 2017-08-16 2017-08-16
US62/546,278 2017-08-16
PCT/US2017/056555 WO2018071794A1 (en) 2016-10-14 2017-10-13 Tyk2 inhibitors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022000195A Division JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2019535807A JP2019535807A (ja) 2019-12-12
JP2019535807A5 JP2019535807A5 (cg-RX-API-DMAC7.html) 2020-11-19
JP7082130B2 true JP7082130B2 (ja) 2022-06-07

Family

ID=61906011

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019541679A Active JP7082130B2 (ja) 2016-10-14 2017-10-13 Tyk2阻害剤およびその使用
JP2022000195A Active JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用
JP2023091142A Withdrawn JP2023106606A (ja) 2016-10-14 2023-06-01 Tyk2阻害剤およびその使用
JP2025202716A Pending JP2026035684A (ja) 2016-10-14 2025-11-25 Tyk2阻害剤およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022000195A Active JP7498200B2 (ja) 2016-10-14 2022-01-04 Tyk2阻害剤およびその使用
JP2023091142A Withdrawn JP2023106606A (ja) 2016-10-14 2023-06-01 Tyk2阻害剤およびその使用
JP2025202716A Pending JP2026035684A (ja) 2016-10-14 2025-11-25 Tyk2阻害剤およびその使用

Country Status (10)

Country Link
US (4) US10323036B2 (cg-RX-API-DMAC7.html)
EP (2) EP3848370B1 (cg-RX-API-DMAC7.html)
JP (4) JP7082130B2 (cg-RX-API-DMAC7.html)
CN (2) CN115448916B (cg-RX-API-DMAC7.html)
AU (3) AU2017342464B2 (cg-RX-API-DMAC7.html)
CA (1) CA3039202A1 (cg-RX-API-DMAC7.html)
ES (1) ES2930198T3 (cg-RX-API-DMAC7.html)
IL (2) IL315777A (cg-RX-API-DMAC7.html)
TW (2) TWI763722B (cg-RX-API-DMAC7.html)
WO (1) WO2018071794A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016138352A1 (en) 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
CN110300590A (zh) 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
AU2018230737B2 (en) 2017-03-08 2022-09-22 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
JP7478142B2 (ja) * 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
EP3801503A4 (en) 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP7619951B2 (ja) 2018-10-15 2025-01-22 武田薬品工業株式会社 Tyk2阻害剤およびその使用
WO2020112937A1 (en) * 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020159904A1 (en) * 2019-01-30 2020-08-06 Bristol-Myers Squibb Company Amide-disubstituted pyridine or pyridazine compounds
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
GB2606804B (en) 2019-07-17 2023-12-27 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
KR20220059519A (ko) * 2019-09-11 2022-05-10 화이자 인코포레이티드 키나제 억제제에 의한 한선염의 치료
US12606556B2 (en) 2020-02-26 2026-04-21 Beone Medicines I Gmbh TYK-2 inhibitor
AR121506A1 (es) 2020-03-03 2022-06-08 Pic Therapeutics Inc Inhibidores del eif4e y sus usos
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
US20240043435A1 (en) 2020-06-22 2024-02-08 Beigene, Ltd. Tyk-2 inhibitor
WO2022083560A1 (zh) * 2020-10-19 2022-04-28 南京药石科技股份有限公司 Tyk2选择性抑制剂及其用途
US20240018153A1 (en) 2020-11-20 2024-01-18 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
US12668594B2 (en) 2020-12-23 2026-06-30 Sudo Biosciences Limited TYK2 inhibitors and uses thereof
TW202302583A (zh) 2021-02-19 2023-01-16 英商蘇多生物科學有限公司 Tyk2抑制劑及其用途
IL305119A (en) 2021-02-19 2023-10-01 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
JP7740849B2 (ja) * 2021-05-04 2025-09-17 シャンハイ ゼイ バイオテクノロジー カンパニー リミテッド 含窒素複素環ピリジン化合物
CN115466289B (zh) * 2021-06-11 2026-07-03 爱科诺生物医药(苏州)有限公司 具有tyk2抑制活性的化合物,包含其的药物组合物,及其应用
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
IL310924A (en) 2021-08-25 2024-04-01 Pic Therapeutics Inc Eif4e inhibitors and uses thereof
US20240390369A1 (en) 2021-09-30 2024-11-28 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
MX2024007713A (es) * 2021-12-23 2024-07-01 Beigene Switzerland Gmbh Formas solidas de un inhibidor de tyk2, metodo de preparacion y uso de estas.
WO2023220046A1 (en) * 2022-05-10 2023-11-16 Biogen Ma Inc. Tyk2 inhibitors
WO2023248010A2 (en) 2022-06-23 2023-12-28 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases
US20240124450A1 (en) 2022-09-21 2024-04-18 Pfizer Inc. Novel SIK Inhibitors
CN115819429A (zh) * 2022-12-13 2023-03-21 成都睿智化学研究有限公司 一种5-氯-2,3-二氢呋喃[2,3-c]吡啶的合成方法
WO2024193689A1 (zh) * 2023-03-23 2024-09-26 广东东阳光药业股份有限公司 吡啶并吡咯衍生物及其在药物中的用途
WO2024211708A1 (en) * 2023-04-06 2024-10-10 Myrobalan Therapeutics, Inc. Tyk2 inhibitors for treatment of glaucoma
WO2024217523A1 (en) * 2023-04-20 2024-10-24 Myrobalan Therapeutics Nanjing Co. Ltd Selective tky2 inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085267A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途
WO2015069310A1 (en) 2013-11-07 2015-05-14 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB599891A (en) * 1944-11-17 1948-03-23 Gen Aniline & Film Corp 1-substituted-2,5-diketo-7-methyl-pyrimido-pyrazoles and process of preparing the same
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
WO2003057689A1 (en) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
JP5236499B2 (ja) 2006-01-27 2013-07-17 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤
KR20080092412A (ko) * 2006-02-06 2008-10-15 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
CA2702647C (en) * 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
CA2681250A1 (en) * 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2299816B1 (en) * 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2588471A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
US9033542B2 (en) * 2010-11-16 2015-05-19 Dialight Corporation LED luminaire utilizing an extended and non-metallic enclosure
KR20140009259A (ko) * 2010-11-19 2014-01-22 에프. 호프만-라 로슈 아게 피라졸로피리딘 및 tyk2 억제제로서 이의 용도
ES2686500T3 (es) * 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
EP2802579B1 (en) * 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
AU2014211856C1 (en) * 2013-02-02 2018-04-12 Centaurus Biopharma Co., Ltd. Substituted 2-aminopyridine protein kinase inhibitor
WO2014210354A1 (en) * 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
US20160222014A1 (en) * 2013-09-10 2016-08-04 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
WO2015073267A1 (en) * 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
NO2721710T3 (cg-RX-API-DMAC7.html) * 2014-08-21 2018-03-31
WO2016138352A1 (en) * 2015-02-27 2016-09-01 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN107849039B (zh) * 2015-06-24 2020-07-03 百时美施贵宝公司 经杂芳基取代的氨基吡啶化合物
TWI763722B (zh) 2016-10-14 2022-05-11 美商林伯士拉克許米公司 Tyk2抑制劑及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085267A1 (ja) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途
WO2015069310A1 (en) 2013-11-07 2015-05-14 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnalpha responses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Gazzetta Chimica Italiana,1957年,Vol.87,p.931-948
J Prakt Chem,1998年,Vol.340,p.408-423
Journal of Heterocyclic Chemistry,2005年,Vol.42, No.6,p.1181-1183
Phosphorus, Sulfur and Silicon,2001年,Vol.176,p.49-59
Polish Journal of Chemistry,1979年,Vol.53, No.12,p.2491-2499
PubChem CID 824807,URL=https://pubchem.ncbi.nlm.nih.gov/compound/824807
Tetrahedron,2016年,Vol.72,p.5754-5761

Also Published As

Publication number Publication date
TW201823243A (zh) 2018-07-01
EP3848370B1 (en) 2025-05-07
US20180155349A1 (en) 2018-06-07
IL265922B2 (en) 2025-02-01
WO2018071794A1 (en) 2018-04-19
AU2017342464A1 (en) 2019-04-18
JP2022037224A (ja) 2022-03-08
EP3526222B1 (en) 2022-08-17
US11220508B2 (en) 2022-01-11
CA3039202A1 (en) 2018-04-19
CN115448916A (zh) 2022-12-09
JP2026035684A (ja) 2026-03-04
EP3526222A4 (en) 2020-08-26
IL265922A (en) 2019-06-30
AU2017342464B2 (en) 2021-09-16
TWI825663B (zh) 2023-12-11
US10793574B2 (en) 2020-10-06
EP3848370A3 (en) 2021-09-15
US10323036B2 (en) 2019-06-18
AU2023237060A1 (en) 2023-10-12
JP7498200B2 (ja) 2024-06-11
AU2023237060B2 (en) 2025-10-02
ES2930198T3 (es) 2022-12-07
JP2023106606A (ja) 2023-08-01
EP3848370A2 (en) 2021-07-14
IL265922B1 (en) 2024-10-01
JP2019535807A (ja) 2019-12-12
US20190284194A1 (en) 2019-09-19
EP3526222A1 (en) 2019-08-21
AU2021225251A1 (en) 2021-09-30
CN115448916B (zh) 2026-04-28
US20210230163A1 (en) 2021-07-29
CN109952303B (zh) 2022-10-21
CN109952303A (zh) 2019-06-28
TW202246264A (zh) 2022-12-01
IL315777A (en) 2024-11-01
US20220073527A1 (en) 2022-03-10
TWI763722B (zh) 2022-05-11

Similar Documents

Publication Publication Date Title
JP7498200B2 (ja) Tyk2阻害剤およびその使用
JP6802263B2 (ja) Tyk2阻害剤およびその使用
JP7530360B2 (ja) Tyk2阻害剤およびその使用
JP6526065B2 (ja) Tyk2阻害剤およびその使用
EP3262049B1 (en) Tyk2 inhibitors and uses thereof
JP2023546996A (ja) Ctps1阻害剤およびその使用
JP2022518505A (ja) Tyk2阻害剤およびその使用
HK40055822B (en) Tyk2 inhibitors and uses thereof
HK40055822A (en) Tyk2 inhibitors and uses thereof
HK40009936A (en) Tyk2 inhibitors and uses thereof
HK40009936B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201008

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220516

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220526

R150 Certificate of patent or registration of utility model

Ref document number: 7082130

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250